Utama › Myasthenia Gravis › New York
Kajian klinikal Myasthenia Gravis di New York
13 kajian untuk Myasthenia Gravis sedang mencari peserta di lokasi di New York.
Bandar di New York
Teks kajian rasmi (Bahasa Inggeris)
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
- Equity Medical, New York
Mengambil pesertaFasa 3
Umur 18 hingga 74 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07217587A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
- Mg0038 10106, Amherst
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07463521ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
- Dent Neurologic Institute - Amherst, Amherst
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT07673627ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
- Dent Neurologic Institute - Amherst, Amherst
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT07294170ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
- Dent Neurologic Institute - Amherst, Amherst
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT07284420A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
- TG Therapeutics Investigational Trial Site, New York
- TG Therapeutics Investigational Trial Site, Rochester
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT06680037A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
- Columbia University Irving Medical Center, New York
Mengambil pesertaFasa 1
Umur 18 hingga 75 · Semua jantina · Dikemas kini 14 Ogo 2026 · NCT07304154RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
- Columbia University, New York
- University of Rochester Medical Center, Rochester
Mengambil pesertaFasa 1/2
Umur 18 hingga 70 · Semua jantina · Dikemas kini 13 Ogo 2026 · NCT06359041Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Site Number - 1036, New York
- Site Number - 1034, New York
Mengambil pesertaFasa 3
Umur 18 hingga 80 · Semua jantina · Dikemas kini 30 Jul 2026 · NCT07039916A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
- Hospital for Special Surgery, New York
- Mount Sinai Health System, New York
- Montefiore Medical Center, The Bronx
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Jun 2026 · NCT06456580A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
- Columbia University Irving Medical Center, New York
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Feb 2026 · NCT06626919Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
- Clinical Trial Site, New Hyde Park
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Feb 2026 · NCT04202341The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis
- Neurological Associates of Long Island, P.C., Lake Success
Mengambil pesertaSukarelawan sihat dialu-alukan
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Apr 2025 · NCT05564936Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.